Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

BBIBP-CorV

Anti-N-Methyl-d-Aspartate receptor (anti-NMDAR) encephalitis and acute multiple sclerosis (MS) relapse: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Etemadifar M, et al. Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. Human Vaccines and Immunotherapeutics 18: 2033540, No. 1, Jan 2022. Available from: URL: http://www.tandfonline.com/loi/khvi20 Etemadifar M, et al. Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. Human Vaccines and Immunotherapeutics 18: 2033540, No. 1, Jan 2022. Available from: URL: http://​www.​tandfonline.​com/​loi/​khvi20
Metadaten
Titel
BBIBP-CorV
Anti-N-Methyl-d-Aspartate receptor (anti-NMDAR) encephalitis and acute multiple sclerosis (MS) relapse: case report
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15364-z

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Nivolumab